 |
InterPro: IPR013201 Proteinase inhibitor I29, cathepsin propeptide
Protein matches
|
UniProtKB Matches: 2244 proteins |
|
Accession
|
IPR013201 Prot_inhib_I29 |
Type
|
Domain |
Signatures
|
|
InterPro Relationships
|
|
Found in
|
IPR013128 Peptidase C1A, papain
IPR015644 Peptidase C1A, cathepsin K
IPR015645 Peptidase C1A, placentally-expressed cathepsin
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
Peptide proteinase inhibitors can be found as single domain proteins or as single or multiple domains within proteins; these are referred to as either simple or compound inhibitors, respectively. In many cases they are synthesised as part of a larger precursor protein, either as a prepropeptide or as an N-terminal domain associated with an inactive peptidase or zymogen. This domain prevents access of the substrate to the active site. Removal of the N-terminal inhibitor domain either by interaction with a second peptidase or by autocatalytic cleavage activates the zymogen. Other inhibitors interact direct with proteinases using a simple noncovalent lock and key mechanism; while yet others use a conformational change-based trapping mechanism that depends on their structural and thermodynamic properties. This entry represents a peptidase inhibitor domain, which belongs to MEROPS peptidase inhibitor family I29. The domain is also found at the N terminus of a variety of peptidase precursors that belong to MEROPS peptidase subfamily C1A; these include cathepsin L, papain, and procaricain (P10056) [1]. It forms an alpha-helical domain that runs through the substrate-binding site, preventing access. Removal of this region by proteolytic cleavage results in activation of the enzyme. This domain is also found, in one or more copies, in a variety of cysteine peptidase inhibitors such as salarin [2].
|
Structural links
|
|
Database links
|
|
Additional Reading
|
|
Weidauer E, Yasuda Y, Biswal BK, Cherny M, James MN, Bromme D.
Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S.
Biol. Chem. 388 2007 331-6
[PubMed: 17338641]
http://dx.doi.org/10.1515/BC.2007.037
|
|
Li Z, Kienetz M, Cherney MM, James MN, Bromme D.
The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex.
J. Mol. Biol. 383 2008 78-91
[PubMed: 18692071]
http://dx.doi.org/10.1016/j.jmb.2008.07.038
|
|
Teno N, Miyake T, Ehara T, Irie O, Sakaki J, Ohmori O, Gunji H, Matsuura N, Masuya K, Hitomi Y, Nonomura K, Horiuchi M, Gohda K, Iwasaki A, Umemura I, Tada S, Kometani M, Iwasaki G, Cowan-Jacob SW, Missbach M, Lattmann R, Betschart C.
Novel scaffold for cathepsin K inhibitors.
Bioorg. Med. Chem. Lett. 17 2007 6096-100
[PubMed: 17911019]
http://dx.doi.org/10.1016/j.bmcl.2007.09.047
|
|
Inagaki H, Tsuruoka H, Hornsby M, Lesley SA, Spraggon G, Ellman JA.
Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode.
J. Med. Chem. 50 2007 2693-9
[PubMed: 17469812]
http://dx.doi.org/10.1021/jm070111+
|
|
Stack CM, Caffrey CR, Donnelly SM, Seshaadri A, Lowther J, Tort JF, Collins PR, Robinson MW, Xu W, McKerrow JH, Craik CS, Geiger SR, Marion R, Brinen LS, Dalton JP.
Structural and functional relationships in the virulence-associated cathepsin L proteases of the parasitic liver fluke, Fasciola hepatica.
J. Biol. Chem. 283 2008 9896-908
[PubMed: 18160404]
http://dx.doi.org/10.1074/jbc.M708521200
|
|
|
InterPro 24.0
|